Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication

dc.authorid0000-0002-2263-6689
dc.authorid0000-0002-2104-6783
dc.contributor.authorOzturk, Oguzhan
dc.contributor.authorDoganay, Levent
dc.contributor.authorÇolak, Yaşar
dc.contributor.authorEnc, Feruze Yilmaz
dc.contributor.authorUlaşoğlu, Celal
dc.contributor.authorOzdil, Kamil
dc.contributor.authorTuncer, İlyas
dc.date.accessioned2025-05-10T19:48:27Z
dc.date.issued2017
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground and study aims: The success rate of Helicobacter pylori (H. pylori) eradication with the classical triple therapy is gradually declining. In this study, we aimed to compare and assess the efficacies of six different eradication regimens including sequential protocols. Patients and methods: Endoscopically confirmed nonulcer dyspepsia patients were enrolled. H. pylori presence was determined either histologically or by a rapid urease test. Treatment-naive patients were randomly assigned to an either one of three 10-day (OAC, OTMB, and OACB) or one of three sequential protocols (OA + OCM, OA + OCMB, and OA + OMDB) (O = omeprazole, A = amoxicillin, C = clarithromycin, T = tetracycline, M = metronidazole, B = bismuth, D = doxycycline). The eradication was assessed 6-8 weeks after the completion of the treatment by a 14C-urea breath test. Results: In total, 301 patients were included. Fifty-two percent of the participants (n = 157) were female, and the mean age was 44.9 years (range = 18-70). The intention to treat (ITT) and per protocol (PP) eradication rate for each regimen is as follows: OAC (ITT = 61.2%, PP = 75%), OTMB (83.3%, 87%), OACB (76.5%, 79.6%), OA + OCM (72.3%, 73.9%), OA + OCMB (82.7%, 89.6%), and OA + OMDB (59.3%, 65.3%). Smoking significantly affected the eradication rate (P = 0.04). Conclusion: In this study, OTMB and OA + OCMB were significantly superior to the triple therapy and succeeded to reach the eradication rate proposed by the Maastricht consensus (over 80%). These two bismuth-containing regimens could be considered for first-line therapy in the regions with high clarithromycin resistance. (C) 2017 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.
dc.description.sponsorshipUmraniye Teaching and Reseal-di Hospital
dc.description.sponsorshipThe authors would like to thank Associated Professor Ebru Zemheri for reviewing the biopsy slides and Arzu Calisgan for her contribution to this study as a biostatistician. This research was funded by internal research funds of Umraniye Teaching and Reseal-di Hospital.
dc.identifier.doi10.1016/j.ajg.2017.05.002
dc.identifier.endpage67
dc.identifier.issn1687-1979
dc.identifier.issn2090-2387
dc.identifier.issue2
dc.identifier.pmid28601610
dc.identifier.scopusqualityQ3
dc.identifier.startpage62
dc.identifier.urihttps://doi.org/10.1016/j.ajg.2017.05.002
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11691
dc.identifier.volume18
dc.identifier.wosWOS:000407522900004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Bv
dc.relation.ispartofArab Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectBismuth
dc.subjectHelicobacter pylori eradication
dc.subjectSequential therapy
dc.subjectTreatment failure
dc.subjectTriple therapy
dc.titleTherapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication
dc.typeArticle

Dosyalar